Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 13/20 | 0.52 |
| ▸ | HTR1A | P08908 | 3/20 | 0.50 |
| ▸ | HTR2A | P28223 | 2/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15016167 | 0.89 | CCR2 (0.54) | CCR2KCNH2KDM4EALDH1A1 | |
| SCHEMBL3150162 | 0.89 | CCR2 (0.56) | CCR2HTR1AHTR2ADRD3KDM4E | |
| SCHEMBL3140818 | 0.88 | CCR2 (0.52) | CCR2KCNH2KDM4EALDH1A1GAA | |
| SCHEMBL15016259 | 0.85 | CCR2 (0.55) | CCR2HTR1AKCNH2KDM4EALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL3139878 | 0.85 | CCR2 (0.52) | CCR2KCNH2 | |
| Hydrochloric Acid SCHEMBL3148843 | 0.85 | CCR2 (0.54) | CCR2HTR1AKCNH2KDM4EALDH1A1 | |
| SCHEMBL3154017 | 0.85 | HTR1A (0.52) | CCR2HTR1AHTR2ADRD3ALDH1A1 | |
| SCHEMBL3139609 | 0.82 | HTR1A (0.52) | CCR2HTR1AHTR2ADRD3ALDH1A1 | |
| SCHEMBL3052714 | 0.81 | CCR2 (0.63) | CCR2KCNH2KDM4EALDH1A1GAA | |
| SCHEMBL3153470 | 0.81 | CCR2 (0.50) | CCR2HTR1AHTR2ADRD3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074083-B1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-06-19 | — | — | EP | claimed |
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-03-25 | — | — | US | claimed |
| EP-2074083-B1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-06-19 | — | — | EP | disclosed |
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, TRPV1 | CCR2 417/4885HTR1A 709/4885HTR2A 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.